During the presentation Arun indicated that Pillar results could be published in the next several weeks, hopefully in time for the SAGES convention, which commences April 2nd. The timeframe to publication keeps narrowing.
I previously noted that during the RBC talk Arun mentioned that one selling point of PINPOINT was that it serves as a replacement endoscopic system and not just another added piece of equipment. Listening to the BarcIays webcast, it became clear that he really was referring to the new PINPOINT which will be unveiled at SAGES. Based on feedback gained in the field, beyond fluorescence and quantification of perfusion, the new PINPOINT will be aimed at replacing all the functions that surgeons are used to using with their old endoscopes: gas insufflation, data capture, and different sizes and shapes of scopes.
These greater capabilities should speed adoption in the OR and increase unit ASP.
Arun said that the average 40% growth rate was likely to result from less than 40% for partnered agreements (Intuitive/FIREFLY and Lifecell/SPY) and greater than 40% for self-vended products (LUNA and PINPOINT). Given the enhancements, better color image presentation, and perfusion quantification, my question is when will renegotiation of the Novadaq/Inutitive licensing and equipment sales agreement (ten year, signed 2009) occur? I don't think Intuitive will wait for expiration to get improved equipment.
buzzy , good point. Probably the idea came from the surgeons themselves.
In any event, this should rapidly increase adoption in the OR. Maybe today's price action is a reflection of that. I appreciate your insightful posts.
Sounded good. 40% growth for 2014 and into the future. If the PPS would follow that trajectory, we could be looking at
29.40 for 2014
41.16 for 2015
57.62 for 2016
80.67 for 2017
How do you like it so far?? :-)